Cochlearia, or fluticasone propionate nasal spray, is one of the commonly used nasal glucocorticosteroids, primarily used for the prevention and treatment of seasonal allergic rhinitis (including choroidal fever) and perennial allergic rhinitis. Its low bioavailability and low systemic side effects make it an ideal topical agent for inflammatory diseases of the nasal cavity and sinuses. This class of drugs is currently the topical drug of choice for the clinical treatment of rhinitis and sinusitis. Glucocorticoids have anti-inflammatory effects, and their anti-inflammatory mechanism is that lipid-soluble glucocorticoid molecules cross the target cell membrane into the cytoplasm, bind to the glucocorticoid receptor, and play an anti-inflammatory role by regulating the transcription of genes, increasing the transcription of anti-inflammatory genes and decreasing the transcription of inflammatory genes. Adverse effects of this drug are mainly confined to the localization of the nasal cavity, such as a feeling of dryness in the nose, and sometimes bleeding from the nose, snot blood, and in very rare cases of improper use, perforation of the nasal septum may occur. When using this drug for the treatment of rhinitis, it is recommended to do so under medical advice.